Aleksander Krag

🚨 NEW: Nearly 780 people die every day in Europe from liver disease — a largely preventable crisis. The new EASL–Lancet Commission calls for urgent policy action on alcohol, diet, viral hepatitis & more. 👉Full report: thelancet.com/commissions-do…

⏰ Reminder: Don’t miss this important conversation on the future of liver health in Europe Liver disease continues to rise across Europe, but strong evidence can lead to meaningful action. Join the launch of the EASL–Lancet Commission 2.0 “From Evidence to Impact: Implementing Sustainable Liver Health in Europe” 📅 30 April 2026 🕒 11:00–13:00 📍 Brussels + online Bringing together policymakers, clinicians, researchers, economists and civil society, this event will focus on: 🔹 Strengthening prevention 🔹 Improving early detection 🔹 Advancing liver care across Europe Hear from global health leaders, Commission experts, and take part in a key discussion on turning recommendations into real-world impact. 👉 View the programme: easl.eu/event/liver-commisio… 👉 Register here: surveymonkey.com/r/LJ9NB6F @DebbieShawcros1 @analleo

🗞️A major new guidance document on steatotic liver disease has just been published online, providing a global, multidisciplinary framework for screening and patient management across the entire disease spectrum. With SLD affecting more than 1 in 3 adults worldwide, the document uses the patient trajectory as its anchor, providing practical recommendations on case finding, risk stratification, referral pathways and stage specific care, from early disease to advanced fibrosis and cirrhosis. All recommendations are categorised as must have or nice to have, enabling adaptation across different healthcare systems and resource settings. 👉Read it now: jhep-reports.eu/action/showP… @FrancqueSven

A key Plenary session is now providing an important update on the joint @AASLDtweets and EASL consensus on clinical trial design and endpoints in MetALD and ALD. The discussion is outlining general considerations for trial design, before moving into phase 2 and 3 endpoints in pre cirrhotic disease, and specific considerations for compensated and decompensated advanced chronic liver disease. Challenges around harmonising endpoints across overlapping phenotypes, the role of biomarkers and imaging, and regulatory expectations are all under careful examination. Patient centred outcomes and emerging surrogate markers are central to shaping the next generation of trials. #SLDSummit @AleksanderKrag @DebbieShawcros1 @NoureddinMD @hlcortezpinto